Login to Your Account



Second Strike on Rituxan as it Fails in Lupus Trial

By Catherine Hollingsworth


Wednesday, April 30, 2008
Still reeling from a negative study of Rituxan in multiple sclerosis patients, Genentech Inc. and Biogen Idec Inc. reported more unfavorable data Tuesday from a Phase II/III study of the drug in lupus patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription